NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results from its first phase II pilot trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew +® CBD (cannabidiol) functional, controlled release chewing gum.
The study, which was conducted at Wageningen University in The Netherlands, was a randomized, placebo controlled, double-blind, cross-over trial aimed at investigating acceptance and overall pain reduction. Enrolled patients suffered from IBS according to the Rome III criteria, as diagnosed by their own physicians. To be included, it was also necessary that patients experienced, according to their own account, at least three pain episodes per week of a predefined intensity (measured by VAS-score). After a one-week run-in period to record baseline parameters, patients received either CanChew+® (with 50 mg CBD) or active placebo chewing gum
... read more at: https://globenewswire.com/news-release/2017/11/21/1198101/0/en/Axim-Biotechnologies-Announces-Phase-IIa-Trial-Results-Validating-its-Proprietary-Cannabinoid-Delivery-Method-for-Treatment-of-Irritable-Bowel-Syndrome-IBS.html